AIM： To perform a meta-analysis of the prevalence of anti-ribosomal P （aRP） antibodies in lupus psychosis, and the odds of psychosis in aRP-positive subjects.METHODS： We identifed articles by searching PubMed, Psy...AIM： To perform a meta-analysis of the prevalence of anti-ribosomal P （aRP） antibodies in lupus psychosis, and the odds of psychosis in aRP-positive subjects.METHODS： We identifed articles by searching PubMed, PsychInfo, and ISI, and the reference lists of identifed studies.RESULTS： Twenty-four studies met the inclusion criteria. Positive aRP antibodies were found in 51% （91 of 179 total cases） of cases of lupus psychosis. There was an almost 3.5-fold increased odds of psychosis in aRP-positive patients （OR = 3.46, 95%CI： 1.97-6.09, P 〈 0.001）. The population attributable risk percentage was 36% for aRP antibodies.CONCLUSION： aRP antibodies are common in lupus psychosis, although the potential mechanism（s） underlying this association remain unclear. Given the overlap between the clinical presentation and risk factors for lupus psychosis and schizophrenia, further investigation of aRP antibodies in schizophrenia is warranted.展开更多
基金Supported by The National Institute of Mental Health(1K23MH098014)Georgia Regents Universityhonoraria from Medscape,Insight Consulting,and Decision Resources Group
文摘AIM： To perform a meta-analysis of the prevalence of anti-ribosomal P （aRP） antibodies in lupus psychosis, and the odds of psychosis in aRP-positive subjects.METHODS： We identifed articles by searching PubMed, PsychInfo, and ISI, and the reference lists of identifed studies.RESULTS： Twenty-four studies met the inclusion criteria. Positive aRP antibodies were found in 51% （91 of 179 total cases） of cases of lupus psychosis. There was an almost 3.5-fold increased odds of psychosis in aRP-positive patients （OR = 3.46, 95%CI： 1.97-6.09, P 〈 0.001）. The population attributable risk percentage was 36% for aRP antibodies.CONCLUSION： aRP antibodies are common in lupus psychosis, although the potential mechanism（s） underlying this association remain unclear. Given the overlap between the clinical presentation and risk factors for lupus psychosis and schizophrenia, further investigation of aRP antibodies in schizophrenia is warranted.
